Derivation and validation of a sensitive IMA cutpoint to predict cardiac events in patients with chest pain. Issue 11 (22nd October 2009)

• Record Type: Journal Article
• Authors: Manini, A F; Ilgen, J; Noble, V E; Bamberg, F; Koenig, W; Bohan, J S; Hoffmann, U
• Is Part Of: Emergency medicine journal. Volume 26:Issue 11(2009)
• Page Start: 791
• Page End: 796
• Publication Date: 2009-10-22
• Subjects: Emergency medicine -- Periodicals; 616.02505
• DOI: 10.1136/emj.2008.068130
• Languages: English
• ISSNs: 1472-0205

Abstract

Abstract : Objectives: In patients with acute chest pain, we derived a cutpoint for ischaemia-modified albumin (IMA) and prospectively validated this cutpoint to predict 30-day major adverse cardiac events (MACEs). Methods: We prospectively recruited a derivation cohort (18-month period) to establish a serum IMA cutpoint targeting 80% sensitivity. This was followed by a prospective validation cohort study of emergency department patients with acute chest pain at two university hospitals over a 3-month period. A MACE was defined as myocardial infarction, revascularisation or death at 30-day follow-up. Results: In the derivation cohort of 151 patients, the IMA cutpoint that achieved 80% sensitivity for MACEs was 75 KU/litre. The sensitivity was prospectively validated in 171 patients consecutively enrolled, of whom 106 underwent multiple-biomarker analysis (19.8% MACE rate, 81% sensitivity of IMA). Furthermore, IMA by itself (81%, p<0.01) and in combination with initial highly sensitive cardiac troponin T (hsTnT) (90%, p<0.001) had significantly higher sensitivity than initial hsTnT (29%) for prediction of MACEs. Conclusions: We prospectively validated the sensitive IMA cutpoint of 75 KU/litre with 80% sensitivity for MACEs in patients with acute chest pain. Our data suggest that IMA alone and in combination with initial hsTnT are more sensitive than the initial hsTnT for MACEs.